Machine Learning

Apogee Acquisition Corp. prices its IPO, joining a resurgent SPAC market with a sharp focus on acquiring a transformative advanced technology company.

With exports soaring to $82 billion, China's massive battery fair will showcase next-gen tech while navigating new mandatory carbon tracking and recycling laws.

Amorepacific Museum of Art unveils its landmark collection show, placing Korean masters in conversation with global art titans and cementing Seoul's cultural power.

With millions of illegal school bus passings a year, new tech like extended stop arms offers a proactive solution. But can it overcome cost and driver apathy?

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Transcendent Aerospace unveils affordable, reusable jet interceptors to combat the growing threat of cheap drones, aiming to flip the script on modern warfare.

Dremio's latest moves in the Apache Iceberg ecosystem, including V3 support and a new board seat, signal a major push for open data standards.

As educators face historic challenges, the American Institutes for Research presents a sweeping research agenda on AI, equity, and student well-being.

The 6th-gen Toyota RAV4 ditches gas engines, betting its all-hybrid lineup and new tech can keep it on top of the hyper-competitive small SUV market.

Despite a guilty plea, a new book by a former FBI agent claims the Idaho Murders case is far from closed, citing flaws in DNA and police work.

After seven years in stealth, Madrid-based Xoople emerges with unicorn status to commercialize a satellite data platform for the coming agentic AI era.

Decoy Therapeutics touts a revolutionary AI platform for multi-virus drugs, but faces financial hurdles. An upcoming investor event could define its future.

Enlyte's acquisition of PartsTrader signals a major shift in the auto claims industry, promising more efficiency but raising questions about competition.

A Charlotte dentist’s late-night parenting struggle sparks a patented invention, disrupting a beloved childhood tradition and making her a national innovator.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.

This April, families nationwide are walking to fund a new strategy for Lennox-Gastaut Syndrome, aiming to slash diagnosis times and find real cures.

Metazoa's new Intelligent Assistant for Salesforce goes beyond diagnostics, promising to actively help admins and developers remediate org complexity.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

New preclinical data for ATNM-400 and Actimab-A shows promise for treating resistant solid tumors and AML, highlighting a new frontier in cancer therapy.